KIR2DL1 and glioblastoma: 44% of KIR2DL1 subsets expressed LFA-1 and were receptor–ligand mismatched against undifferentiated and susceptible ICAM-1 expressing GBM cells propagated in stem cell medium, potentially implicating KIR2DL1/HLA-C2 receptor–ligand interactions in the efficacy.